Ascent Group LLC Reduces Stock Position in Haleon PLC Sponsored ADR $HLN

Ascent Group LLC cut its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 75.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,218 shares of the company’s stock after selling 99,875 shares during the period. Ascent Group LLC’s holdings in Haleon were worth $298,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hanson & Doremus Investment Management boosted its holdings in shares of Haleon by 234.1% in the second quarter. Hanson & Doremus Investment Management now owns 2,372 shares of the company’s stock worth $25,000 after acquiring an additional 1,662 shares during the period. Banque Transatlantique SA bought a new stake in shares of Haleon during the 1st quarter valued at $27,000. Golden State Wealth Management LLC raised its stake in shares of Haleon by 107.6% during the 2nd quarter. Golden State Wealth Management LLC now owns 2,721 shares of the company’s stock valued at $28,000 after purchasing an additional 1,410 shares during the period. Ransom Advisory Ltd purchased a new stake in Haleon during the 1st quarter worth about $31,000. Finally, Hilltop National Bank bought a new position in Haleon in the 2nd quarter worth about $33,000. Institutional investors own 6.67% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on HLN. Morgan Stanley reiterated an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. The Goldman Sachs Group raised shares of Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. Barclays cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Trading Down 0.9%

Shares of Haleon stock opened at $10.02 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42. The firm has a market cap of $44.60 billion, a PE ratio of 25.68 and a beta of 0.19. The company has a 50 day simple moving average of $9.67 and a two-hundred day simple moving average of $9.64.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.